Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Linaprazan glurate - Cinclus Pharma

Drug Profile

Linaprazan glurate - Cinclus Pharma

Alternative Names: SND-001; X-842

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cinclus Pharma
  • Developer Cinclus Pharma; Shanghai Pharmaceutical Group
  • Class Anti-inflammatories; Antibacterials; Gastric antisecretories; Small molecules
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Oesophagitis

Most Recent Events

  • 27 Nov 2023 Cinclus Pharma expects market approval for linaprazan glurate in Oesophageal motility disorders in 2027
  • 27 Nov 2023 Cinclus Pharma plans a phase III trial for Oesophageal motility disorders in US, Europe and one additional region in 2024
  • 14 Oct 2023 Updated adverse events data from a phase II LEED trial in Oesophagitis presented at the 31st United European Gastroenterology Week (UEG-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top